The Efficacy of Xuebijing Injection on Sepsis
NCT03238742 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 1817
Last updated 2021-01-05
Summary
The Efficacy of Xuebijing Injection in Adult Patients with Sepsis
Conditions
Interventions
- DRUG
-
Xuebijing Injection
100ml Xuebijing Injection every 12 hours for 5 days
- DRUG
-
normal saline
200ml normal saline every 12 hours for 5 days
Sponsors & Collaborators
-
National Health and Family Planning Commission, P.R.China
collaborator OTHER_GOV -
Southeast University, China
lead OTHER
Principal Investigators
-
Qiu Haibo, Dr. · Southeast University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- TRIPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-10-20
- Primary Completion
- 2019-07-28
- Completion
- 2020-01-08
Countries
- China
Study Locations
More Related Trials
-
Clinical Research on Shenfu Injection in Septic Patients
NCT06157320 ·Status: RECRUITING ·Phase: NA
-
Study of Multiple-dose Kukoamine B Mesilate in Sepsis Patients
NCT03237728 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of Early Goal-Directed Therapy to Perfusion and Metabolism of Brain
NCT02706379 ·Status: UNKNOWN ·Phase: NA
-
Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients
NCT02449928 ·Status: UNKNOWN ·Phase: NA
-
Neutrophil Elastase Inhibitor in Treatment of ARDS Patients With Mechanical Ventilation Caused by Sepsis
NCT05672472 ·Status: UNKNOWN ·Phase: NA
-
The Predictive Value of Hepatocyte Growth Factor and Soluble Receptor s-Met in Sepsis
NCT03340649 ·Status: UNKNOWN
-
Shenfu Injection Improves Arterial Vascular Reactivity
NCT03749525 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Effects of Terlipressin on Renal Perfusion in Patients With Septic Shock
NCT04948372 ·Status: COMPLETED ·Phase: NA
-
Validation of Molecular and Protein Biomarkers in Sepsis
NCT04289506 ·Status: UNKNOWN
-
Efficacy and Pharmacokinetics of Meropenem in Severe Septic Patients
NCT03645668 ·Status: COMPLETED ·Phase: PHASE4
-
Sivelestat for Acute Respiratory Distress Syndrome Due to COVID-19
NCT05697016 ·Status: UNKNOWN ·Phase: NA
-
Efficacy and Safety of Methylene Blue in the Treatment of Severe Septic Shock
NCT06481410 ·Status: RECRUITING ·Phase: NA
-
Use of Dobutamine in Patients With Sepsis and Maintained Hypoperfusion After Initial Volemic Resuscitation.
NCT05953142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Kukoamine B Mesilate in Sepsis Patients
NCT04803955 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of Dexmedetomidine on Respiratory Function and Inflammatory Responses in Patient With Sepsis Undergoing Cleaning Focus of Infection
NCT02842437 ·Status: UNKNOWN ·Phase: NA
-
Methylene Blue in Sepsis: A Randomized Controlled Trial
NCT00486174 ·Status: WITHDRAWN ·Phase: NA
-
Study on the Establishment of a System for Early Warning and Prognostic Evaluation of Patients With Sepsis
NCT05229328 ·Status: UNKNOWN
-
Protective Effect of Sivelestat Sodium on ARDS in Patients With Sepsis
NCT04973670 ·Status: UNKNOWN ·Phase: PHASE3
-
The Effect and Mechanism of lncRNA NBR2 Regulating Endothelial Pyroptosis by Targeting GSDMD in Sepsis
NCT04427371 ·Status: UNKNOWN
-
High MAP in Septic Shock With Hypertension
NCT01443494 ·Status: COMPLETED ·Phase: NA
-
Methylene Blue in Severe Sepsis and Septic Shock
NCT01797978 ·Status: UNKNOWN ·Phase: PHASE3
-
Potential Diagnostic and Prognostic Value of microRNAs for the Patients of Sepsis-induced Myocardial Injury
NCT02835573 ·Status: UNKNOWN
-
Identification of Cardiovascular and Molecular Prognostic Factors for the Mid- and Long-term Outcome of Sepsis
NCT03620409 ·Status: COMPLETED
-
Protocol-driven Hemodynamic Support for Patients With Septic Shock
NCT00335907 ·Status: UNKNOWN ·Phase: NA
-
Continuos Terlipressin Infusion in Septic Shock
NCT01697410 ·Status: UNKNOWN ·Phase: NA